Costs of newly diagnosed neovascular age-related macular degeneration among medicare beneficiaries, 2004-2008
PURPOSE: To examine associations between newly diagnosed neovascular age-related macular degeneration and direct medical costs.METHODS: This retrospective observational study matched 23,133 Medicare beneficiaries diagnosed with neovascular age-related macular degeneration between 2004 and 2008 with a control group of 92,532 beneficiaries on the basis of age, sex, and race.The index date for each case-control set corresponded to the first diagnosis for the case.Main outcome measures were total costs per patient and age-related macular degeneration-related costs per case 1 year before and after the index date.RESULTS: Mean cost per case in the year after diagnosis was $12,422, $4,884 higher than the year before diagnosis.Postindex costs were 41% higher for cases than controls after adjustment for preindex costs and comorbid conditions.Age-related macular degeneration-related costs represented 27% of total costs among cases in the postindex period and were 50% higher for patients diagnosed in 2008 than in 2004.This increase was attributable primarily to the introduction of intravitreous injections of vascular endothelial growth factor antagonists.Intravitreous injections averaged $203 for patients diagnosed in 2004 and $2,749 for patients diagnosed in 2008.CONCLUSION: Newly diagnosed neovascular age-related macular degeneration was associated with a substantial increase in total medical costs.Costs increased over time, reflecting growing use of anti-vascular endothelial growth factor therapies.
Qualls, LG; Hammill, BG; Wang, F; Lad, EM; Schulman, KA; Cousins, SW; Curtis, LH
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)